Psychedelic Trials Are Going Intravenous. Ketamine Clinics Already Have That Room
An Australian biotech cleared an early hurdle this month for a study of psilocin delivered by IV drip. The headline number, 72 patients across eight conditions, is not the interesting part. The delivery method is. Psychedelic developers are moving toward infusions, and infusions are what ketamine clinics already do.
Adding a second medicine starts with protecting the margin on the first. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| What was approved | An Australian ethics committee cleared a Phase 1b/2a study of intravenous psilocin. Trial notification is still pending |
| The study design | 72 patients across nine cohorts and eight conditions, which is eight patients per condition, with safety as the primary endpoint |
| Why the route matters | Intravenous delivery lets clinicians control onset, intensity and duration, and stop the infusion if a session turns |
| The clinic angle | Titration, monitored chairs and staff trained to sit with an altered state already exist in ketamine practices |
| What it does not prove | No efficacy conclusions are possible from eight patients per condition, and nothing here is approved for use |
Looking for treatment? Find Spravato clinics (which is covered by insurance) and ketamine clinics closest to you as well as other psychedelic therapies in your area.
What Actually Happened
Entropy Neurodynamics received ethics committee approval in Australia for a Phase 1b/2a study of TRP-8803, an intravenous formulation of psilocin. Psilocin is the compound the body converts psilocybin into. The study will run with Swinburne University at a cost of about A$3.2 million.
Read the fine print before you get excited. This is an ethics committee clearance, not a regulatory approval, and the trial notification is still pending. The design spreads 72 participants across nine cohorts covering anorexia, body dysmorphic disorder, OCD, generalized anxiety, PTSD, treatment resistant depression, fibromyalgia and irritable bowel syndrome. That is eight patients per condition, with safety as the primary endpoint.
Eight patients cannot establish that a treatment works. This study is designed to show the approach is tolerable and worth pursuing.
The Route Is the Story
The company’s argument for IV delivery is worth reading closely, because it is an operational argument rather than a scientific one.
Swallowed psilocybin passes through the gut, where absorption varies between patients. Blood levels drift. Sessions can run six hours or longer, and once the dose is down, nobody can take it back. Intravenous delivery changes each of those variables. Clinicians reach target levels quickly, hold them steady, and shorten the session. If a patient becomes distressed, the infusion stops.
We covered an earlier version of this idea in 2024, when researchers described an IV psilocybin protocol compressing the experience toward ten minutes. The direction has held.
You Already Own the Hard Part
Now apply that to your treatment floor. An IV psychedelic protocol requires vascular access, precise titration, continuous monitoring, a quiet room a patient can occupy for hours, and staff who stay calm while someone moves through an altered state.
That list describes a ketamine clinic. It does not describe a psychiatrist’s office or a telehealth platform. The infrastructure barrier that keeps most providers out of psychedelic delivery is the barrier your practice cleared years ago.
Where the Gaps Would Be
Two differences deserve planning rather than assumption.
Chair time is the first. A ketamine infusion turns a room in under two hours. Psychedelic protocols in current trials run longer, and the therapy component in many designs adds staff hours a ketamine schedule does not carry. Revenue per room per day changes accordingly.
Documentation is the second. Trial protocols demand structured preparation, monitoring records and integration notes. Practices already capturing outcomes systematically will adapt fastest, which is one more reason that habit pays for itself.
The Pattern Behind Every Recent Deal
Zoom out and this fits what we have been tracking all summer. Eli Lilly paid billions for a psychedelic pipeline. AbbVie bought a compound. Analysts now speculate about which developer gets acquired next.
Every one of those transactions buys a molecule. None of them buys a treatment room. The delivery layer stays where it already is, which is the argument running through our look at why the next wave of clinic consolidation will be different.
What to Watch
Treat this specific trial as a signal rather than an event. First dosing is expected this quarter, and early cohorts should finish before year end. Safety data will arrive first, and only for very small groups.
The company also points to earlier work in binge eating disorder, which we covered when the pilot results published. Those numbers came from a small open label study, so read them as encouraging rather than settled.
The practical move is unglamorous. Keep outcomes documented, keep compliance clean, and keep monitoring capacity in reserve. Our acquisition readiness checklist covers most of it, because the same records that make a clinic attractive to a buyer make it ready for a second medicine.
